Creating new medications to help reduce opioid withdrawal symptoms
Official title: Development of small molecule therapeutics for mitigating opioid withdrawal syndrome
Funded at Evodenovo, INC. · NIH-10785942 · Data updated 2026-11-12
This study is looking for new medications that can help people going through opioid withdrawal by targeting a specific receptor in the brain, aiming to provide pain relief without the risk of addiction, and patients may have the chance to try these new treatments in clinical trials.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evodenovo, INC. NIH-funded |
| Lab location | 1 site (andover, UNITED STATES) |
| Project start | April 15, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $880,957 |
| NIH project number | 2R44DA053844-02 |
| Project ID | NIH-10785942 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are experiencing opioid withdrawal symptoms or have a diagnosis of opioid use disorder.
✕Less likely to help
Patients who are not currently using opioids or do not have a history of opioid use disorder may not benefit from this research.
What this research studies
This research focuses on developing small molecule compounds that can alleviate opioid withdrawal syndrome by targeting a specific receptor known as GPR139. The approach aims to enhance pain relief while minimizing the risk of dependence associated with traditional opioid treatments. By utilizing advanced techniques in medicinal chemistry and genetic neuronal models, the research team is working to create effective therapies that could improve the management of opioid use disorder. Patients may be involved in clinical trials to evaluate the safety and efficacy of these new medications.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for individuals experiencing opioid withdrawal, ultimately improving their quality of life.
How similar studies have gone: Previous research has shown promise in targeting specific receptors to mitigate opioid dependence, suggesting that this approach could be a viable option for treatment.
Where this research is happening
-
Evodenovo, INC.
andover, United States Active
Researchers
- Principal investigator: Labed, Sid Ahmed — Evodenovo, INC.
- Study coordinator: Labed, Sid Ahmed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.